[Evaluation of gene chip technology for high risk type human papillomavirus in cervical cancer screening].
[Evaluation of gene chip technology for high risk type human papillomavirus in cervical cancer screening].
复制标题
高危型人乳头瘤病毒基因芯片技术在宫颈癌筛查中的评价
DOI：
10.3760/j:issn:0376-2491.2006.05.006
复制
发表时间：
2006
影响因子：
--
通讯作者：
Y. Qiao
中科院分区：
文献类型：
--
作者：
Rui;Jufang Shi;Qing;R. Wu;Ni Li;L. Wu;Yan;Qian Wang;Zhi;B. Liu;Y. Qiao
目的
探讨人乳头瘤病毒（HPV）基因芯片技术在宫颈癌筛查中的临床应用价值。
方法
对深圳市某社区1137名15-59岁妇女进行了以人群为基础的横断面筛查研究。应用杂交捕获2（hc 2）技术和基因芯片技术检测宫颈脱落细胞中高危型人乳头瘤病毒。同时进行液基细胞学检查（LCT）。HPV阳性LCT ≥不典型鳞状细胞（ASCUS）和HPV阴性LCT ≥低度鳞状上皮内病变（LSIL）者行阴道镜下活检。以病理结果为金标准评价两种HPV检测方法。
结果
共获得122例活检标本。病理检查无宫颈癌病例，宫颈上皮内瘤变（CIN）III级3例，CIN II级11例，CIN I级36例，慢性宫颈炎及鳞状上皮化生69例，正常宫颈3例。hc 2法和基因芯片法的HPV阳性率分别为14.0%和9.8%，hc 2法的HPV阳性率高于基因芯片法（P < 0.001），两者符合率中等（kappa = 0.498）。的. HPV阳性率沿着宫颈病变级别的增高而增高（P < 0.05）。hc 2检测高危型HPV的敏感性、特异性、准确性、阳性前值、阴性前值、阳性似然比和阴性似然比分别为100%、87.1%、87.3%、8.8%、100%、7.7和0.000;基因芯片的阳性率分别为78.6%、91.1%、90.9%、9.9%、99.7%、8.8%和0.235。
结论
目前hc 2高危型HPV检测仍是宫颈癌筛查较好的方法。基因芯片技术可与hc 2相媲美，但对宫颈高度病变的敏感性有待提高。
OBJECTIVE
To investigate the clinical value of gene chips technology for human papillomavirus (HPV) in cervical cancer screening.
METHODS
A population-based cross-sectional screening study was conducted among 1137 women aged 15-59 in a community, Shenzhen city. Hybrid capture 2 (hc2) and gene chip technology were performed to examine the high risk type human papillomavirus in the exfoliated cervical cells. Liquid-based cytology test (LCT) was also performed at the same time. The HPV-positive women with LCT > or = atypical squamous cells of undetermined sign (ASCUS) and the HPV-negative women with LCT > or = low grade squamous intraepithelial lesion (LSIL) underwent biopsy under colposcopy. The pathological results were used as the gold standard to evaluate the two HPV test methods.
RESULTS
Totally 122 biopsy specimens were obtained. Pathological examination showed no cervical cancer case, 3 cases of grade III cervical intraepithelial neoplasia (CIN), 11 cases of grade II CIN, 36 cases of grade I CIN, 69 cases of chronic cervicitis and metaplasia of squamous epithelium, and 3 cases of normal cervix. The HPV-positive rate was 14.0% by hc2 and 9.8% by gene chips with a HPV-positive rate by hc2 higher than that by gene chips (P < 0.001) and an mediocre accordance rate between these methods (kappa = 0.498). The. HPV-positive rate increased along with the increase of the grade of cervical lesions (P < 0.05). The sensitivity, specificity, accuracy, positive prevalue, negative prevalue, positive likelihood ratio and negative likelihood ratio of hc2 for high-risk HPV were 100%, 87.1%, 87.3%, 8.8%, 100%, 7.7 and 0.000, respectively; and those of gene chips were 78.6%, 91.1%, 90.9%, 9.9%, 99.7%, 8.8 and 0.235 respectively.
CONCLUSION
At present hc2 high risk HPV testing is still the better method for cervical cancer screening. Gene chips technology is able to rival hc2 except that its sensitivity for cervical high grade lesions need be improved.